Biotech


  • Professional headshot of Erin Duffy
    Image attribution tooltip

    Permission granted by Asia Kepka

    Q&A

    Her antibiotic company failed. Now she’s helping others avoid the same fate.

    The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.

    By Oct. 6, 2022
  • A wood cutout of a person wearing a tie, holding a telescope and standing on a set of four arrows of differing sizes.
    Image attribution tooltip
    iStock via Getty Images

    C-suite shake-ups at 23andMe, Moderna signal new stages of growth

    With their latest personnel moves, these life sciences companies are preparing for major business shifts.

    By Oct. 5, 2022
  • Cancer cells
    Image attribution tooltip
    koto_feja via Getty Images

    To stay on the leading edge of oncology, AbbVie knows it has to take risks

    In a field that has seen rapid progress but ongoing areas of unmet need, AbbVie is betting on emerging tech.

    By Kelly Bilodeau • Oct. 4, 2022
  • hiring stock
    Image attribution tooltip
    Stock via Getty Images

    The 2 areas in life sciences most in need of talent

    The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.

    By Oct. 4, 2022
  • cell therapy infusion
    Image attribution tooltip
    Stock via Getty Images
    Q&A

    It’s electric — speeding up the cell therapy process for scalability

    To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

    By Alexandra Pecci • Oct. 4, 2022
  • digital clinical trials
    Image attribution tooltip
    Stock via Getty Images
    Q&A

    Clinical trials haven’t harnessed the digital revolution — TransCelerate’s latest initiative aims to change that

    The nonprofit’s VP of portfolio management discussed its “most transformative” digital initiative to date.

    By PharmaVoice staff • Oct. 3, 2022
  • A scale is foregrounded against the sky.
    Image attribution tooltip
    zennie via Getty Images

    How do Biogen-Eisai’s two Alzheimer’s drugs stack up?

    Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.

    By Sept. 30, 2022
  • Samantha Dale Strasser headshot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Pepper Bio’s Samantha Dale Strasser

    The co-founder of Pepper Bio entered the biotech world three years ago with the goal of transforming drug discovery through the emerging discipline of transomics.

    By Sept. 28, 2022
  • Autism stock
    Image attribution tooltip
    Stock via Getty Images
    Q&A

    Why precision medicine could be the next frontier in treating autism

    Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.

    By Kelly Bilodeau • Sept. 27, 2022
  • Katharine Knobil
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Agilent Technologies’ Dr. Katharine Knobil

    As the first chief medical officer of the diagnostic testing company, Dr. Katharine Knobil is focused on moving the science forward beyond precision oncology to liquid biopsy.

    By Sept. 14, 2022
  • Colonies of bacteria in MacConkey agar
    Image attribution tooltip
    Md Saiful Islam Khan via Getty Images

    Feds could soon bring COVID-style fight to superbug threat

    COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.

    By Sept. 13, 2022
  • Bubble
    Image attribution tooltip
    Petrovich9 via Getty Images

    From the ‘go-go days’ to a bubble crunch — the biotech sector faces its next challenge

    The highs of the sector in early 2021 gave way to a bear market that persisted into the second half of this year — but there's hope the bubble hasn't popped for good.

    By Sept. 12, 2022
  • Cindy Mesaros
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Foresite Capital’s Cindy Mesaros

    The longtime marketing pro details her fascinating career journey and how she’s positioning early stage health companies to thrive. 

    By Sept. 7, 2022
  • CFO
    Image attribution tooltip
    joel-t via Getty Images
    First 90 Days

    First 90 Days: Adaptive Biotech’s Tycho Peterson

    A long-time analyst, Tycho Peterson brings his business savvy to the C-suite at Adaptive, where he began as CFO in June with a knowledge of what works and what doesn't in the diagnostics space.

    By Sept. 1, 2022
  • A 3D illustration of sickled cells in blood
    Image attribution tooltip
    Artur Plawgo via Getty Images

    Pharma’s renewed sickle cell investment lifts a once-shirked disease

    Pfizer's $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.

    By Kelly Bilodeau • Sept. 1, 2022
  • Glass vials of Moderna COVID-19 vaccine.
    Image attribution tooltip
    Gabriel Kuchta via Getty Images

    Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes

    The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.

    By Aug. 31, 2022
  • inside cell
    Image attribution tooltip
    Stock via Getty Images
    Profile

    Leading the industry’s next potential game-changer in drug discovery

    Rachel Meyers, chief scientific officer at Faze Medicines, is helping guide the company towards the development of biomolecular condensates — an emerging field that could transform drug discovery.

    By Alexandra Pecci • Aug. 29, 2022
  • A light blue puzzle depicting rows of workers has scattered pieces missing, showing a yellow background underneath.
    Image attribution tooltip
    iStock via Getty Images

    Moderna, Eli Lilly and Schrödinger seek to boost financial and people strategies with key new hires

    How the latest personnel shifts are impacting each company and the industry at large. 

    By Aug. 24, 2022
  • Money pills
    Image attribution tooltip
    cagkansayin via Getty Images

    Patents, pandemics and pricing: a peek at the top drug from every big pharma

    A look at how the biggest pharma companies in the world and their top-selling drugs fared in the first half of the year.

    By Aug. 22, 2022
  • President Biden signs the Inflation Reduction Act surrounded by members of congress and backed by American flags in the White House.
    Image attribution tooltip
    Drew Angerer via Getty Images

    3 ways pharma can prep for Biden’s sweeping drug pricing policies

    Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.

    By Aug. 18, 2022
  • Pill
    Image attribution tooltip
    Liudmila Chernetska via Getty Images

    Inventing the COVID vax pill: a matter of convenience and durability

    Recent data from Vaxart’s phase 1 trial of its COVID-19 inoculation pill shows potential.

    By Kelly Bilodeau • Aug. 17, 2022
  • Nasal spray
    Image attribution tooltip
    Evgenyi_Eg via Getty Images

    Right under our noses: Could COVID-19 vaccines be better as nasal spray?

    Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.

    By Kelly Bilodeau • Aug. 16, 2022
  • Image attribution tooltip
    E+ via Getty Images

    As pharma M&A ramps up, U.S. execs are bullish on more deals

    What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

    By Aug. 11, 2022
  • cell therapy infusion
    Image attribution tooltip
    Stock via Getty Images

    4 ways to nail the launch of your cell therapy

    A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

    By Aug. 10, 2022
  • Seen from behind, a clinician is using a cell phone and checking a patient's electronic health record on a laptop.
    Image attribution tooltip
    iStock via Getty Images
    Q&A

    How real world evidence is impacting rare disease drug development

    ICON’s Will Maier shares how a more patient-focused approach to trials is leading to alternatives for randomization.

    By Kim Ribbink • Aug. 9, 2022